Biogen INC 10-Q quarterly reports

Biogen Inc. announced its Q2 2026 financial results, highlighting revenue growth driven by rare disease and specialized immunology products, alongside increased R&D and SG&A expenses due to strategic acquisitions and product launches.

Biogen Inc. reported a 1.9% increase in total revenue to $2.48 billion and a 31.1% rise in diluted EPS to $2.15 for the first quarter of 2026.

Biogen Inc. reported a 2.8% increase in total revenue for Q3 2025, driven by strong performance in rare disease products and LEQEMBI, while reducing R&D expenses.

Biogen's second quarter 2025 saw a 7.3% increase in total revenue driven by strong Alzheimer's collaboration and contract manufacturing, despite a 1.1% decline in net product revenue primarily from its Multiple Sclerosis portfolio.

Biogen's Q1 2025 results show a revenue increase driven by new product launches, but a decrease in earnings due to higher expenses and restructuring initiatives.

Biogen's Q3 2024 results show a revenue decrease, driven by declines in MS product sales, partially offset by growth in rare disease revenue and strategic acquisitions.

Biogen's second quarter 2024 results show a slight revenue increase and a decrease in diluted earnings per share, with notable growth in rare disease product revenue.

Biogen's first quarter results show a decrease in revenue offset by cost-cutting measures and new product contributions.